These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29151572)

  • 1. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
    Cetin AE; Stevens MM; Calistri NL; Fulciniti M; Olcum S; Kimmerling RJ; Munshi NC; Manalis SR
    Nat Commun; 2017 Nov; 8(1):1613. PubMed ID: 29151572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
    Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
    Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
    Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
    BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogenic or antiestrogenic therapies for multiple myeloma?
    Sola B; Renoir JM
    Mol Cancer; 2007 Sep; 6():59. PubMed ID: 17888187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
    Xu P; Jiang YF; Wang JH
    Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferative effect of levamisole on human myeloma cell lines in vitro.
    Ramanadham M; Nageshwari B
    J Immunotoxicol; 2010; 7(4):327-32. PubMed ID: 20860474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma.
    Vatolin S; Phillips JG; Jha BK; Govindgari S; Hu J; Grabowski D; Parker Y; Lindner DJ; Zhong F; Distelhorst CW; Smith MR; Cotta C; Xu Y; Chilakala S; Kuang RR; Tall S; Reu FJ
    Cancer Res; 2016 Jun; 76(11):3340-50. PubMed ID: 27197150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
    Clemens J; Seckinger A; Hose D; Theile D; Longo M; Haefeli WE; Burhenne J; Weiss J
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):281-91. PubMed ID: 25477008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.
    Xie B; Xu Z; Hu L; Chen G; Wei R; Yang G; Li B; Chang G; Sun X; Wu H; Zhang Y; Dai B; Tao Y; Shi J; Zhu W
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line.
    Durusu İZ; Hüsnügil HH; Ataş H; Biber A; Gerekçi S; Güleç EA; Özen C
    Leuk Res; 2017 Apr; 55():33-40. PubMed ID: 28122281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.